AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments for diseases such as cancer, Alzheimer's disease, autoimmune disorders ...

Invenra will leverage its B-Body® bispecific antibody platform from monoclonal antibody discovery to optimized panels of bispecific leads. Orion will be responsible for the selection of targets ...

Under the terms of the agreements, Invenra will leverage its B-Body® bispecific antibody platform from monoclonal antibody discovery to optimized panels of bispecific leads. Orion will be responsible ...

A team of researchers at Åbo Akademi University in Finland made a surprising discovery. They found that Talin-1, a protein ...

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics Orion Corporation ("Orion") and Invenra Inc. ("Invenra ...

In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibody discovery and development.

Now it is shown that allosteric signalling membrane proteins can be engineered through such networks, revealing a broader space of designable protein interactions and functions. The Melt (Membrane ...

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life.

The PIF/Harbinger-derived ADF-IL protein recruits KAT2B to drive its nuclear translocation and local chromatin acetylation, ...